---
title: "Obefazimod (ABX464) in Ulcerative colitis: Special populations"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Special populations. Topics: Hepatic impairment: phase 1 pharmacokinetic study in mild and moderate impairment; Renal impairment: phase 1 pharmacokinetic study; Renal and hepatic laboratory exclusions in the ABTECT induction trials; Pregnancy, breastfeeding, and contraception in the ABTECT trials; 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/special-populations"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Hepatic impairment: phase 1 pharmacokinetic study in mild and moderate impairment

> “A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.”
> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 11 Mar 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505299-31-00](https://ctis.eu/trial/2023-505299-31-00)

> “(ii) a trial in participants with mild and moderate hepatic impairment compared to matched control normal liver function participants, for the purposes of assessing pharmacokinetics, safety and tolerability in this population, for which we enrolled 30 participants.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.8-2"></a>

### Renal impairment: phase 1 pharmacokinetic study

> “A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.”

Source: [EU Clinical Trials Information System 2024-514561-20-00](https://euclinicaltrials.eu/ctis-public/view/2024-514561-20-00)

<a id="topic-2.1.2.8-3"></a>

### Renal and hepatic laboratory exclusions in the ABTECT induction trials

> “Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula)”
> “Total serum bilirubin > 1.5 x upper limit of normal (ULN) (except if related to pre-existing and documented Gilbert syndrome)”
> “Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 x ULN”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.8-4"></a>

### Pregnancy, breastfeeding, and contraception in the ABTECT trials

> “WOCBP subject who is pregnant or breast-feeding at screening, or intends to become pregnant during the study, or male subject with WOCBP partner who intends to be pregnant during the study.”
> “WOCBP should not be administered obefazimod until pregnancy is excluded and should use at least one highly effective method of contraception (failure rate < 1% when used consistently and correctly) depending on their country, during therapy with obefazimod and through the 4-week safety follow-up procedures.”
> “Sexually active male subjects participating in this study should use condoms for the duration of the active treatment period and through the 4-week safety follow-up procedures after the last dose of study medication.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.8-5"></a>

### Pregnancy: reports in ABTECT maintenance Part 1

| Event | Placebo (N = 192) | Obefazimod 25 mg (N = 193) | Obefazimod 50 mg (N = 195) |
| --- | --- | --- | --- |
| Pregnancy | “0” | “0” | “2 (1.1%)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-2.1.2.8-6"></a>

### Contraception for male participants: phase 1 study in healthy Japanese men

> “Males receiving the study treatment and their partners must agree to use a highly effective contraceptive method during the study and for 6 months after the last dose of study drug.”

Source: [ClinicalTrials.gov NCT05032560](https://clinicaltrials.gov/study/NCT05032560)

<a id="topic-2.1.2.8-7"></a>

### Older adults: participants aged 65 years or older in the ABTECT induction trials

> “Among the 1272 randomized and treated pts in ABTECT trials, 1183 were <65 yo and 89 were ≥65 yo”
> “Among pts <65 yo, TEAEs occurred in 59.8%, 49.5%, and 50.3% of those receiving Obe-50, Obe-25, and PBO, respectively.”
> “For patients ≥65 yo, rates were 65.9%, 38.9%, and 55.6%.”
> “Headache was the most frequent TEAE when treated with Obe across all age groups.”
> “Rates of serious TEAEs and TEAEs leading to study drug discontinuation were similar between Obe and PBO.”
> “In both ABTECT induction trials, obefazimod demonstrated consistent efficacy and safety in the elderly population, with no new or unexpected safety findings.”

Source: [Yarur et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/04/abivax-poster-elderly-yarur-ddw-2026.pdf)

<a id="topic-2.1.2.8-8"></a>

### Pediatric development: European paediatric investigation plan

> “the paediatric population from birth to less than 2 years of age;”
> “From 2 years to less than 18 years of age”
> “2-part, multi-centre, double-blind induction and maintenance study to evaluate the efficacy, safety, tolerability and PK of obefazimod in paediatric patients with moderately to severely active ulcerative colitis aged from 2 years to less than 18 years.”
> “By June 2029”

Source: [EMA paediatric investigation plan decision, March 2025 (2025)](https://www.ema.europa.eu/en/documents/pip-decision/ema-pe-0000189672-ema-decision-20-march-2025-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod_en.pdf)

<a id="topic-2.1.2.8-9"></a>

### Adolescents aged 16 to 17 years in the ABTECT induction trials

> “Pharmacokinetic (PK) modeling and simulations show that the PK profile of obefazimod is expected to be the same in subjects aged 16 to 18 years old compared with older subjects.”
> “However, no adolescents will be recruited in the EU/EEA and Ukraine, or from any other country unless authorized by the respective Regulatory Authorities and IEC-IRB.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.8-10"></a>

### Pediatric minitablet formulation: relative bioavailability study in adults

> “The sponsor is developing a pediatric minitablet formulation as part of the overall pharmaceutical development strategy.”
> “The study aims to investigate the relative bioavailability of the 50mg minitablet compared to the adult obefazimod 50 mg capsule in adult healthy volunteers.”

Source: [ClinicalTrials.gov NCT07453784](https://clinicaltrials.gov/study/NCT07453784)

Additional sources: [EMA paediatric investigation plan decision P/0205/2024 (2024)](https://www.ema.europa.eu/en/documents/pip-decision/p-0205-2024-ema-decision-14-june-2024-acceptance-modification-agreed-paediatric-investigation-plan-obefazimod-emea-003196-pip01-22-m01_en.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
